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Introduction
Hypoglycaemia, defined by a plasma glucose level <3.0 mmol/L 
(54 mg/dL), results from failure to maintain normal plasma 
glucose levels through complex homeostatic mechanisms. 
Hypoglycaemia is a relatively common clinical scenario, 
particularly in patients with diabetes mellitus (DM), 
treated with insulin therapies or sulphonylurea drugs. 
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Hypoglycaemia presents clinically with symptoms in three 
main categories: (I) autonomic sympatho-adrenal activation 
(sweating, tremor and palpitations); (II) neuroglycopenia 
(impaired mental concentration, aggressive behaviour, 
ataxia, blurred vision, impaired consciousness, impaired 
vision, speech and memory, paralysis, seizures and loss of 
consciousness), and; (III) malaise (nausea and headache) 
(1-3). Symptoms of hypoglycaemia vary according to age, 
ability to mount an effective sympatho-adrenal response and 
use of certain concurrent medications such as beta-blockers 
that effectively dampen or prevent any sympatho-adrenal 
response to hypoglycaemia (1).  
The human brain relies upon a continuous supply of 
glucose, as an obligate fuel source (1). Therefore, the brain 
has an inherent vulnerability to any acute interruption to 
the supply of glucose, such as occurs during hypoglycaemia. 
Accordingly, complex evolutionary counter-regulatory 
mechanisms exist (that oppose the regulatory effect of 
insulin), to mitigate the potentially harmful and life-
threatening consequences of hypoglycaemia (1). These 
include an increase in the endogenous production of 
glucose through glycogenolysis and gluconeogenesis, 
through a reduction in endogenous insulin release from 
the pancreatic beta cells, enhanced glucagon release from 
the pancreatic alpha cells, and finally release of adrenaline 
from the adrenal medulla that also promotes further release 
of hepatic glucose (1). To complement these important 
counter-regulatory physiological changes in response to 
acute hypoglycaemia, there is also a behavioural response, 
mediated through appetitive changes, to promote the 
increased consumption of food (1).
Although less common, hypoglycaemia that occurs 
outside of the context of DM and DM-related therapies 
(insulin and sulphonylureas), represents an important 
clinical scenario. Of the many potential causes of 
hypoglycaemia, a relatively uncommon, but nonetheless 
important group includes tumour-induced hypoglycaemia 
(TIH). TIH associates with multiple unique clinical 
challenges that relate primarily to the accurate and timely 
diagnosis and effective, individually tailored management. 
A prerequisite of the former is clinical suspicion of 
hypoglycaemia. Unfortunately, recurrent hypoglycaemia can 
be easily missed for a variety of reasons, including effective 
counter-regulatory responses (e.g., eating-behaviours), 
lack of a detailed and accurate history, a perceived lack of 
relevance and awareness amongst patients and healthcare 
professionals respectively, inadequate biochemical work-
up, concurrent use of therapies such as beta-blockers and 
idiosyncratic and unusual presentations of hypoglycaemia, 
particularly in older patients. For these reasons, it seems 
likely that there may be a missed diagnosis of TIH in 
at least a proportion of patients. However, even when a 
clinical suspicion of recurrent hypoglycaemia prompts 
timely referral, the diagnostic work-up of TIH poses its 
own challenges, and essentially relies upon the occurrence 
of hypoglycaemia (either spontaneous or induced following 
a prolonged fast). There are specific challenges with 
effective management also, including the need for a multi-
disciplinary approach. 
In this concise narrative review, we provide an overview 
of the underlying pathogenesis and clinical features of TIH. 
We explore the diagnostic work-up for TIH, and effective 
management strategies. We also provide suggestions for 
how to address some of the common challenges encountered 
clinically in the accurate and timely diagnosis and effective 
management of TIH. We present the following article in 
accordance with the narrative review reporting checklist 
(available at https://dx.doi.org/10.21037/jlpm-20-110).  
Methods
We performed a narrative literature review using PubMed 
and search-term “Tumour-Induced Hypoglycaemia”, with 
articles written in English.
Pathogenesis and clinical features of TIH
TIH is an umbrella term that incorporates any episode 
of hypoglycaemia that originates from an underlying 
tumour. Broadly, the two main categories of TIH include 
insulinoma and non-islet cell tumours (NICTs), the 
pathogenesis of each differing fundamentally. Accordingly, 
each group of tumours has a characteristic biochemical 
profile, and demands a specific and precise management 
strategy. It is hard to overstate the importance of obtaining 
an accurate and timely diagnosis of TIH, including the 
particular subtype, as this determines the formulation of 
an appropriate, individualised and effective management 
strategy. Misdiagnosis of TIH could have serious 
ramifications and result in inadequate and inappropriate 
treatment, with associated deleterious outcomes for the 
patient. In this section, we provide an overview of the 
pathogenesis and clinical features of each main category of 
TIH, insulinoma and NICTs, summarized in Table 1.
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Insulinoma
Insulinomas are tumours of the pancreatic beta cells, first 
identified >90 years ago in a patient with co-occurrence 
of functional  hyperinsulinaemia and an is let  cel l 
tumour (4). Insulinomas are usually small, sporadic and well 
circumscribed intra-pancreatic tumours, although can be 
distributed throughout the pancreas (5,6). Insulinomas are 
the commonest TIH-related cause of hypoglycaemia, the 
vast majority (between 90% and 95%) being benign (5), and 
malignancy occurring in only a small minority (5.8%) (6). 
Insulinomas are relatively rare with an incidence of 4 cases 
per million per year, based on a 60-year observation period 
in a US-based epidemiological study (6). Despite their 
rarity though, insulinomas are the commonest functioning 
pancreatic neuroendocrine tumours (NETs), accounting 
for 20–30% of such cases (6). In rare cases (between 4% 
and 6%), insulinomas associate with multiple endocrine 
neoplasia type 1 (MEN1) (5). Insulinomas occur frequently 
in the fifth decade, with a slight preponderance in women 
(5,6) and characteristically over-produce insulin, resulting 
in hyperinsulinaemia. Hypoglycaemia ensues, which results 
in stimulation of counter-regulatory responses. Importantly 
however, due to the autonomous over-production of insulin 
from the insulinoma-related tumour cells, there is a lack 
of appropriate suppression of insulin release, with ongoing 
propensity for recurrent hypoglycaemia. 
The clinical features of insulinoma include “Whipple’s 
triad”: (I) onset of hypoglycaemic symptoms after fasting 
or heavy exercise; (II) biochemical confirmation of fasting 
hypoglycaemia, and; (III) relief of hypoglycaemic symptoms 
following restoration of normal blood glucose levels (7). 
The clinical features of insulinoma-related hypoglycaemia 
include symptoms typical of neuroglycopenia (8-10), and 
sympatho-adrenal activation (8-10). Classically, precipitation 
of symptoms of insulinoma-related hypoglycaemia occurs 
following fasting or exercise. However, based on data from 
a longitudinal study, a minority (6%) of cases of insulinoma 
present with just postprandial symptoms, and 21% of cases 
present with both fasting and postprandial symptoms (11). 
Of note, there is often a delayed diagnosis of insulinoma. 
Data from one study showed a median time to diagnosis 
of insulinoma of 24 months, and frequent confusion with 
seizure disorder and other neuropsychiatric disorders (5,12). 
Importantly, patients with insulinoma often experience 
persistent hunger, as an appropriate counter-regulatory 
behavioural response to recurrent hypoglycaemia. 
Changes in appetite can promote hyperphagia (including 
frequent small meals to lessen and prevent symptoms of 
hypoglycaemia), with resultant weight-gain and obesity as 
common clinical features of insulinoma (12). 
NICTs
Recurrent hypoglycaemia from NICT origin is  a 
paraneoplastic syndrome. NICTs mainly comprise tumours 
of mesenchymal origin such as sarcomas, fibromas, fibro 
sarcomas, solitary fibrous tumours, leiomyosarcomas, 
Table 1 Clinical and pathogenic features of tumour-induced hypoglycaemia (TIH) and therapeutic strategies in patients with insulinoma and 
NICT
Clinical/pathogenic feature Insulinoma NICT
Incidence (number of cases per million per year) 4 1
Origin Pancreatic beta-cells Mesenchymal (fibromas, sarcomas, 
GIST)
Malignancy Usually benign Large and/or metastatic tumours
Clinical features of hypoglycaemia Recurrent hypoglycaemia
(Whipple’s triad)
Recurrent hypoglycaemia (Whipple’s 
triad)
Change in body weight Often increased (increased appetite and 
caloric ingestion)
Increased or decreased (from the 
effects of the tumour)
Therapeutic strategy (surgical) Surgical resection
where possible
Surgical resection or embolization/
ablation
Therapeutic strategy (medical) Diazoxide; somatostatin analogues; high-
dose glucocorticoid therapies 
Supra-physiological doses of rhGH
GIST, gastrointestinal stromal tumours; NICT, non-islet cell tumour; rhGH, recombinant human growth hormone.
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haemangiopericytomas and renal cell carcinomas (13,14). 
NICT-related hypoglycaemia usually stems from large and/
or metastatic tumours, but can occur at any time during 
the natural disease course (13). Gastrointestinal stromal 
tumours (GIST) are the commonest mesenchymal tumours 
of the gastrointestinal tract, mainly affecting the stomach, 
and often asymptomatic until they cause symptoms related 
to mass effect such as gastrointestinal bleeding, perforation 
or obstruction (13). GIST can present with NICT-related 
recurrent hypoglycaemia prior to any other mass effect-
related symptoms. NICTs differ fundamentally from 
insulinomas in their secretion profiles. Rather than over-
production of insulin, NICTs produce and secrete excessive 
amounts of (incompletely processed) insulin-like growth 
factor 2 (IGF2). This incompletely processed and high-
weight form of IGF2 is also referred to as “big”-IGF2. 
Overall, high serum levels of big-IGF2 cause hypoglycaemia 
through cross-reactivity with the insulin receptor, mediated 
by inhibited hepatic glycogenolysis, gluconeogenesis and 
glucose release, and continued glucose utilization by skeletal 
muscle (13). Although counter-regulatory mechanisms 
ensue, including suppression in the release of insulin 
from the pancreatic beta cells, autonomous production of 
big-IGF2 persists, and underlies chronic, persistent and 
recurrent hypoglycaemic episodes. 
Each NICT is capable of production and secretion 
of large quantities of big-IGF2, with hepatocellular and 
gastric carcinomas the most common causes of NICT-
related hypoglycaemia (15-17). Overall,  recurrent 
hypoglycaemia predated the diagnosis of NICTs in 48% of 
cases in one multicentre study (17). However, the overall 
occurrence of NICT-related recurrent hypoglycaemia 
is a rarity; its incidence of 1 case per million population 
per year being around 25% that of insulinomas (14,18). 
The clinical features of NICT-related hypoglycaemia are 
similar to those of insulinoma described above. Classically, 
recurrent and persistent hypoglycaemia manifests with both 
neuroglycopenic features, sympatho-adrenal stimulation 
and the occurrence of Whipple’s triad (3). Although 
the clinical features of NICT-related TIH are usually 
restricted to the tumour itself and its associated recurrent 
hypoglycaemia, rarely other clinical features can also 
ensue. In one case report of a NICT resulting from a 
pelvic clear cell sarcoma, manifesting with hypoglycaemia 
and elevated serum levels of big-IGF2, the patient also 
presented with acromegaloid skin changes (soft tissue 
facial swelling, skin tags and nuchal hyperpigmentation), 
that resolved following resection of the underlying tumour 
and normalised serum big-IGF2 levels (19). This case 
highlights the potential for cross-reactivity of big-IGF2 
with the insulin-like growth factor 1 (IGF1) receptor, with 
associated acromegaloid features.  
The pathogenesis of hypoglycaemia from NICTs 
implicates a central role for big-IGF2. In this context, it is 
also necessary to briefly discuss IGF1, the counterpart of 
IGF2; a detailed discussion of the physiology and regulation 
of IGF1 and IGF2 is beyond the scope of the present 
review, and has been previously reviewed elsewhere (20,21). 
In brief, both IGF1 and IGF2 are structurally similar to 
insulin and secreted primarily from the liver in normal 
physiology (20,22). Growth hormone (GH) stimulates the 
hepatic production of IGF1, whilst pituitary production of 
GH is itself regulated by serum levels of IGF1. In this way, 
GH and IGF1 form essential elements of the somatotropic 
axis. Conversely, IGF2 is independent of any influence 
from GH, and does not form any part of the somatotropic 
axis (20). Serum IGF1 and IGF2 act on the IGF1 and 
IGF2 receptors, respectively, in addition to cross-reactivity 
with the insulin receptor (23). Estimations show that the 
effect of IGFs on lowering plasma glucose levels (through 
their effects on the insulin receptor) is 10-fold less than 
that of a similar serum concentration of insulin. However, 
although the serum concentration of IGFs is around 1,000-
fold greater than that of insulin (24,25), the majority of 
IGFs (90%) within the circulation are bound to IGF-
binding proteins (IGFBPs), with IGFBP3 binding to over 
95% of circulating IGFs, thereby blocking their plasma 
glucose-lowering potential (26,27). Importantly though, 
as aforementioned, the big-IGF2 produced from NICTs 
is a larger, immature peptide that stems from abnormal 
post-translational processing, due to insufficient enzyme-
related modification (20,21). Big-IGF2 has a lesser affinity 
for binding to IGFBPs. Accordingly, the free component of 
big-IGF2 within the serum is 20-fold greater than that of 
IGF2. This results in a greater glucose-lowering potential 
of big-IGF2 (from cross-reactivity of the free-component 
of big-IGF2 with the insulin receptor), compared to that 
of IGF2 (much of which is bound to IGFBPs and therefore 
comparatively less cross-reactive with the insulin receptor) (28). 
The increased action of free (unbound) serum big-IGF2 
on peripheral insulin receptors results in increased glucose 
uptake into cells, and consequent hypoglycaemia. Increased 
serum levels of free big-IGF2 in patients with NICTs 
can also disrupt the production of GH from the pituitary 
through cross-reactivity with IGF1 receptors and therefore 
enhanced negative feedback effects, with consequent 
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diminishment of downstream hepatic IGF1 release, thereby 
disrupting one of the counter-regulatory responses to 
hypoglycaemia, and further contributing towards persistent 
and recurrent hypoglycaemic episodes (21,28). We provide 
an overview of the pathogenesis of hypoglycaemia in TIH 
from NICT in Figure 1. 
Diagnosis of TIH
Having considered the pathogenesis and clinical features 
of insulinoma and NICT-related hypoglycaemia, it is 
important to consider the diagnostic challenges of these two 
conditions. As outlined, an accurate and timely diagnosis of 
TIH is essential for the implementation of an appropriate 
and effective management plan. Diagnostic work-up 
should always start with a detailed and comprehensive 
history. As alluded to, recurrent hypoglycaemia can occur 
with both insulinoma and NICTs. Although the timing 
of hypoglycaemia can be variable, episodes often occur 
during the night or early morning before breakfast, when 
the mitigating effects of food are less likely to occur. Due 
to the behavioural and appetitive changes induced by 
recurrent hypoglycaemia, weight gain can also occur with 
TIH, although the absence of weight gain should not 
detract from considering such a diagnosis. There may also 
be specific clinical features such as weight loss that relate to 
the underlying NICT. Ultimately, however, the diagnosis of 
TIH and the differentiation between insulinoma and NICT 
depends on detailed and accurate biochemical testing.
Biochemical investigation
The biochemical investigation of hypoglycaemia depends 
upon the successful inducement of a hypoglycaemic episode, 
during which there is analysis of further samples. In the 
case of TIH, the gold standard test is the 72-hour fast. 
This usually requires a patient to attend as an in-patient 
either in a ward-based setting or on a specialist endocrine 
Reduced  counter- 








































Figure 1 Overview of the pathogenesis of hypoglycaemia in patients with non-islet cell tumours (NICTs), and the therapeutic benefits of 
recombinant human growth hormone (rhGH) therapy. GH, growth hormone; IGF1, insulin-like growth factor 1; IGF2, insulin-like growth 
factor 2; big IGF2, incompletely processed and high-weight form of IGF2; IGFBP3, insulin-like growth factor binding protein 3; Pit, 
pituitary.
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investigation unit. During such a test, access to water is 
unlimited, although there is complete restriction of any 
caloric ingestion, with the aim to induce a hypoglycaemic 
episode. Occurrence of hypoglycaemia in both insulinoma 
and NICT is usually characterized clinically by the onset 
of Whipple’s triad, with associated biochemical evidence 
(plasma blood glucose level <3.0 mmol/L; 54 mg/dL). 
In the case of insulinoma, hypoglycaemia occurs in the 
context of inappropriate hyperinsulinaemia (≥18 pmol/L), 
associated elevation of serum C-peptide levels (≥0.2 nmol/L) 
and plasma proinsulin levels (≥5 pmol/L) and suppression 
of plasma β-hydroxybutyrate levels (≤2.7 mmol/L) (5). 
C-peptide is a molecule produced when endogenous 
proinsulin is cleaved to form insulin, and is secreted from 
the pancreatic beta-cells in equimolar concentrations to 
insulin (29). An elevated serum C-peptide level in the 
context of raised serum levels of proinsulin and insulin 
indicates the presence of either an insulinoma or factitious 
use of sulphonylurea drugs (a class of oral glucose-
lowering drugs that mainly act by stimulating pancreatic 
insulin secretion) (29). To diagnose TIH, it is important 
to exclude exogenous insulin administration as a potential 
cause of hypoglycaemia through appropriately elevated 
serum C-peptide levels (circulating C-peptide levels are 
not affected by exogenous insulin administration), and use 
of insulin secretagogue therapies (such as sulphonylureas) 
through either plasma or urine screening for metabolites of 
sulphonylureas (30). 
Distinct from insulinoma, those patients with NICT-
related hypoglycaemia manifest hypoinsulinaemia in the 
context of hypoglycaemia, but with a characteristically 
increased ratio of serum IGF2-to-IGF1. Suppression 
of serum IGF1 in patients with NICT occurs due to 
suppression of GH secretion from increased serum levels 
of free big-IGF2 (17). This provides an explanation for a 
raised IGF2-to-IGF1 ratio as a characteristic biochemical 
signature of NICTs [identifiable via thin-layer liquid 
chromatography mass spectroscopy (LC/MS)] (31). Patients 
with NICT-related hypoglycaemia also typically have low 
serum levels of proinsulin, C-peptide, beta-hydroxybutyrate 
and IGFBP3 (3,32). However, there is some heterogeneity 
in the biochemical manifestation of NICT-related 
hypoglycaemia. We present the characteristic biochemical 
signatures of TIH during hypoglycaemia in Table 2. 
Although nominally a 72-hour fasting test, the duration 
of the test depends on the occurrence of hypoglycaemia 
(marking its conclusion). In fact, 95% of cases only require 
48 hours of fasting to induce hypoglycaemia (with 99% 
of cases requiring 72 hours) (33). Indeed, there are a few 
exceptional case reports of insulinoma diagnosis despite a 
normal 72-hour fasting test (34). 
Immunoassays form the main biochemical diagnostic 
technique for TIH (35). One important limitation 
of immunoassays relates to their immunoreactivity 
against numerous peptides, thereby generating a total 
concentration of all such peptides in any sample, rather 
than the concentration of each individual peptide (35). This 
is relevant to NETs as these tumours may release partially 
processed pro-hormones that then contribute towards the 
total measured concentration produced by the assay (35). 
To address such a challenge, an alternative approach, and 
one increasingly applied to clinical practice including some 
cases of NET (glucagonoma and insulinoma) is LC/MS (35), 
which requires less plasma and represents a cheaper option 
than current traditional immunoassay-based methods. 
LC/MS may therefore be a viable future option for 
application to TIH diagnostics (35). Unfortunately, there 
is no commercially available immunoassay for big-IGF2 
(16,21). Furthermore, the current IGF2 assay may not 
distinguish between total and free levels of IGF2. This is 
relevant as NICT-related hypoglycaemia usually associates 
with increased serum free big-IGF2, although total serum 
level of IGF2 may not change (21,28,36). Despite these 
challenges in assaying serum big-IGF2 and IGF2, it is 
Table 2 Pattern of clinical serum biochemical results from cases of tumour-induced hypoglycaemia (TIH) compared with exogenous insulin and 
sulphonylurea usage (3)
Condition Insulin Proinsulin C-peptide Beta-hydroxybutyrate
NICT Low Low Low Low
Insulinoma High High High Low
Exogenous insulin High Low Low Low
Sulphonylurea use High High High Low
NICT, non-islet cell tumour.
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possible to use northern blotting on tumour tissue to detect 
increased levels of IGF2-mRNA (13,37).
For patients without any occurrence of hypoglycaemia 
within 48 hours of a fast, premature curtailment of the 
entire 72-hour fast remains an option (33,38). However, 
the gold standard test is a 72-hour fast, early termination of 
which may result in a failure to demonstrate hypoglycaemia 
(with Whipple’s triad) in a small percentage of patients 
who are asymptomatic at 48 hours. Furthermore, in those 
patients with NICTs, it may require a full 72 hours for full 
beta-cell suppression to occur (33). Most patients undergo 
admission for a 72-hour fasting test, which does limit its 
utility and applicability. To mitigate such a challenge, in 
one study from the US, patients were fasted overnight 
and then attended an outpatient clinic the next day for 
hypoglycaemia monitoring. In 40% of patients, this 
approach was sufficient for a biochemical diagnosis based 
on the occurrence of hypoglycaemia (patients underwent 
admission if hypoglycaemia did not then occur in the 
outpatient setting) (33). 
Imaging
Following biochemical confirmation of TIH (with 
differentiation of insulinoma versus NICT), there is 
usually a requirement to localize the tumour through 
focused imaging modalities (11). In one longitudinal study 
that explored the use of imaging studies for insulinoma 
introduced into clinical practice until 2007, non-invasive 
techniques such as transabdominal ultrasound and triple 
phased spiral CT or MRI (modalities from the 2003–2007 
study cohort), enabled the diagnosis of 80% of cases of TIH. 
Diagnosis of the remaining 20% of cases required the use 
of invasive techniques, such as Endoscopic Ultrasonography 
(EUS) or Selective Arterial Calcium Stimulation Testing 
(SACT) (11). Implementation of such invasive tests reduces 
the need for blind surgical exploration of insulinomas, with 
data from the Mayo Clinic showing sensitivity rates of 75% 
and 93% for EUS and SACT, respectively (11).  
Unusual causes of TIH
Although this review focuses on the main causes of TIH 
(insulinoma and NICT), there are reports from the 
literature of rare cases of TIH that do not fit into either 
of these categories. It is important, therefore, to be aware 
of the potential for such cases when investigating for 
TIH. In one reported case of a patient with dementia 
and recurrent falls, there was identification at post-
mortem of multiple hepatic lesions that were proinsulin-
secreting NETs (39). This case highlights the importance 
of including measurements of serum proinsulin in the 
diagnostic work-up of TIH. Of note, there is variable cross-
reactivity of proinsulin with the C-peptide assay, dependent 
upon the specific assay used (39). Although a relatively 
faster clearance of serum insulin compared to C-peptide 
can influence the ratio of insulin to C-peptide, in this case 
the ratio was markedly low, with disproportionately higher 
levels of serum C-peptide compared to insulin (due to 
cross-reactivity of proinsulin with the C-peptide assay) (39). 
Therefore, in cases of markedly elevated serum proinsulin 
and C-peptide compared with serum insulin, there should 
be consideration of a diagnosis of proinsulinoma. Whilst 
the vast majority of cases of proinsulinoma originate within 
the pancreas, rare cases (such as the one described here) are 
extra-pancreatic in origin. 
Rare cases of NICTs that may present with the 
biochemical profiles of raised serum IGF2-to-IGF1 ratios 
from over-production of big-IGF2 from the tumour, include 
hepatocellular carcinoma (40), pulmonary blastoma (41), 
and disseminated ductal carcinoma of the breast (42). 
Furthermore, in rare cases of TIH, a diagnosis of NICT as a 
cause of recurrent hypoglycaemia may not be apparent from 
clinical and imaging details, highlighting the importance 
of careful biochemical assessment. In one reported case of 
recurrent hypoglycaemia, the underlying cause was NICT 
originating from multiple pulmonary metastases from a 
poorly differentiated thyroid carcinoma (43). Biochemistry 
confirmed an increased serum concentration of big-IGF2, 
and undetectable levels of serum insulin, IGF1 and GH. 
Furthermore, on retrospective review, there had been a 
gradual reduction in the serum concentration of glycated 
haemoglobin associated with a corresponding increase in 
the estimated volume of the pulmonary metastases (43). 
Other unusual cases of hormonally mediated recurrent 
hypoglycaemia may not always implicate underlying 
tumours. In one reported case, a patient with a history of 
head trauma and reactive hypoglycaemia, developed more 
frequent and severe hypoglycaemic episodes (44). Following 
exclusion of TIH, the underlying cause of recurrent 
hypoglycaemia was severe isolated GH deficiency, which 
responded well to treatment with recombinant human (rh) 
GH therapy (44). A report of a rare case of antepartum 
pituitary failure presenting as recurrent hypoglycaemia and 
acute onset of headache in a pregnant woman with type 
1 DM further highlights the importance of normal pituitary 
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function in the mitigation of recurrent hypoglycaemia (45). 
A further report describes the potential effects of opioid 
analgesia on the occurrence of hypoglycaemia resulting 
from secondary adrenal insufficiency (46). Finally, any 
disturbance of the central regulation of the hypothalamo-
pituitary adrenal and/or somatotropic axes can manifest 
clinically with recurrent hypoglycaemia (including multiple 
other clinical features, particularly in children) (47). 
Therefore, the endocrine diagnostic work-up of recurrent 
hypoglycaemia should include consideration of pituitary 
adenoma (including both functioning and non-functioning 
sub-types) and their prior treatment with surgery and/or 
radiotherapy, and other hypothalamo-pituitary pathologies 
(including genetic and/or congenital defects) (47).
The rare and unusual endocrine cases outlined in 
this sub-section highlight the importance of a thorough 
biochemical and endocrine assessment in the investigation 
of recurrent hypoglycaemia, and a preparedness for unusual 
and rare presentations of TIH.
TIH post-bariatric surgery
A special rare case of TIH (although one shrouded in 
controversy) may occur as a complication of Roux-en-Y 
gastric bypass (RYGB) surgery (2). The overall prevalence 
of hypoglycaemia following RYGB is estimated at 0.2–1% 
of patients, and is more prevalent in women (2,48). In 
one case series, patients (n=6) who developed endogenous 
hyperinsulinaemic hypoglycaemia following RYGB underwent 
partial pancreatectomies as a treatment strategy. Pathological 
assessments suggested nesidioblastosis (2,49). Although a 
subsequent case series revealed similar results (50), further 
reports have questioned the diagnosis of nesidioblastosis 
(versus increased nuclear diameter of beta cells) (51), 
and suggest that post-mortem autolysis may alter cell 
size and therefore histological appearance (2). Dietary 
modification represents the first-line of therapy in post-
RYGB hypoglycaemia, with a low-carbohydrate diet less 
likely to cause hypoglycaemia (2,52). Medical therapies for 
post-RYGB include α-glucosidase inhibitors that reduce 
the postprandial rise in glucose and insulin, but are limited 
by their gastrointestinal side-effects (2). Other medical 
therapeutic strategies include somatostatin analogues 
that inhibit insulin secretion and reduce gastrointestinal 
motility, and occasionally diazoxide (53), although 
there is a lack of evidence for the longer-term efficacy 
of such therapies (2). Although partial pancreatectomy 
as a treatment option of post-RYGB surgery has had 
variable results (54-58), a majority of patients appear 
to have continuation of their hypoglycaemic symptoms 
post-pancreatectomy, and therefore this surgical option 
has been abandoned for the purpose of alleviating 
hypoglycaemia (2). Finally, surgical reversal of RYGB 
provides a reasonable option in those patients with severe 
and refractory hypoglycaemia post-RYGB (2,59). 
Management of TIH
A detailed discussion of the management strategies for TIH 
is beyond the scope of this concise review, and is covered 
comprehensively elsewhere (2). Here, we only outline 
the basic principles of management. Due to the rarity of 
TIH, evidence for its effective management is restricted 
to case series and individual case reports (16). Broadly, the 
management of TIH sub-divides into two main strategies: (I) 
surgical excision or ablation of the underlying insulinoma or 
NICT, and; (II) medical and lifestyle management of TIH-
associated hypoglycaemia. 
Surgical excision
Where possible, there should be complete surgical resection 
of an insulinoma or NICT causing hypoglycaemia, and if 
successful, this often cures further hypoglycaemic episodes (16). 
Surgical excision of insulinoma may not be possible in the 
context of smaller tumours that are undetectable on imaging 
techniques. Furthermore, complete surgical resection of 
some NICT tumours may not be possible due to their size 
and accessibility, especially in the context of metastases (16). 
Surgical resection allows for immunohistochemical 
confirmation of tumour sub-type (60). In cases of NICTs 
where surgical excision is not possible, ablative measures are 
an option (60). Selective embolization and radiofrequency 
ablation can help in the alleviation of hypoglycaemia (13). 
However, rapid necrosis of the tumour that can occur 
during such procedures can result in an increase in 
circulating levels of big-IGF2, manifesting in further 
hypoglycaemia. Therefore, caution is required during 
ablation and embolization procedures for NICTs (13).
Medical and lifestyle management
In  pa t ient s  who present  acute ly  wi th  recurrent 
hypoglycaemia relating to TIH, it is important to initiate 
prompt management with intravenous hydration and 
glucose infusions (13). In the outpatient setting, and prior 
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to any surgery for TIH, there is usually provision of dietary 
advice to patients, including frequent small meals to reduce 
the frequency of hypoglycaemia. 
Medical therapy for insulinomas includes administration 
of diazoxide (200–600 mg per day, orally in divided doses), 
with the dose gradually titrated to alleviate symptoms (9). 
Somatostatin analogues represent an alternative medical 
therapy, although insulinomas variably express somatostatin 
receptors (9,61). Overall, use of diazoxide or somatostatin 
analogues control the hypoglycaemic symptoms of 
insulinoma in 50–60% of patients (5,62,63). Glucocorticoids 
are the most documented medical treatment to prevent 
hypoglycaemia. As a bridge to surgery, high doses of 
glucocorticoids are used (equivalent to prednisolone 
30–60 mg per day) (16,64). Indeed, a useful illustration 
of the effectiveness of high-dose glucocorticoids as a 
treatment option in this context is the reported prevention 
of hypoglycaemia from its use as a monotherapy (16,64). 
However, some cases of TIH are resistant to even very high 
doses of glucocorticoids, in which recurrent hypoglycaemia 
can persist (16). 
Regarding the effective management of TIH from 
NICT, the treatment of choice is supra-physiological 
doses rhGH, at 3–12 mg per day (16,65). The efficacy of 
rhGH occurs via several mechanisms that include increased 
levels of IGF1, IGFBP3 and suppression of the peripheral 
uptake of glucose (with an overview in Figure 1) (16,65,66). 
Furthermore, administration of glucocorticoid therapies in 
patients with TIH from NICTs also decrease serum levels 
of IGF2. Use of glucocorticoid and rhGH therapies can 
enable palliative weaning off intravenous glucose in some 
patients with NICT-related hypoglycaemia (13). However, 
neither rhGH nor glucocorticoid therapies have undergone 
randomised trials. Furthermore, there remains a theoretical 
possibility of rhGH-induced stimulation of tumour cells 
when used in patients with NICTs (16). We provide a 
summary of the therapeutic options for insulinoma and 
NICT-induced hypoglycaemia in Table 1. 
Future directions
Most rare conditions suffer from a relative lack of high-
quality evidence that stems from randomised controlled 
trials. By definition, a rare condition simply lacks enough 
cases to power adequately any meaningful placebo-
controlled trial. This poses a problem for conditions such 
as TIH. Instead of a reliable and robust evidence-base, our 
practice in the investigation and management of such rare 
conditions usually rests on case series, case reports and 
expert opinion. Often, clinical management of such rare 
conditions remains constant over decades with each new 
generation of healthcare professional adopting the accepted 
practice of their immediate senior colleagues. Such an 
approach is entirely understandable in the face of deficient 
high-quality evidence. However, we should still question 
our approach towards the investigation and management 
of rare conditions, and not simply accept that current 
approaches are necessarily the best just because no one 
has done it differently. In this context, TIH presents some 
specific challenges, outlined here, that need to be addressed 
in future clinical practice:
Lack of clinical awareness
As with many rare conditions, TIH suffers from a broader 
lack of awareness amongst healthcare professionals 
in general. Many non-specialist colleagues may never 
encounter a patient with TIH during their entire career. 
This perhaps explains why there can be a delay in the 
diagnosis of TIH, through a lack of clinical suspicion and 
timely referral due to clinical inexperience and reduced 
awareness. Despite its rarity though, TIH is nonetheless 
a condition that demands accurate and timely diagnosis 
and effective individualised management strategies, 
given the implications of unrecognised and untreated 
recurrent hypoglycaemia for the patient and for society 
in general (including road safety for example). Moreover, 
as hypoglycaemia is potentially fatal, it is important 
that healthcare professionals receive proper education 
regarding the key clinical features of hypoglycaemia, and 
the possibility of underlying TIH. Raising awareness of this 
important condition amongst colleagues could save lives. 
Since specialist investigation and management is required, 
it is also essential that there is prompt referral of any patient 
with a clinical suspicion of TIH to an Endocrine specialist 
colleague.  
Diagnostic challenges
Investigation of recurrent hypoglycaemia presents specific 
challenges given the need to provoke a hypoglycaemic 
episode. This usually requires in-patient admission, 
which is often difficult given the extreme pressure on 
hospital beds in our modern-day era. Furthermore, 
patients may be reluctant to come into a hospital for a 
3-day fasting test for many reasons. As outlined earlier, 
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one alternative would be for patients to attend an 
outpatient investigation unit for one day following an 
overnight fast, thereby avoiding the need for hospital 
admission in at least a subgroup of patients. However, 
even with this approach, many patients will subsequently 
require hospital admission (33). Further challenges 
include the timing of samples: regular monitoring of blood 
glucose is required, and many samples (including serum and 
urine) need sending to the biochemistry lab concurrently 
and during a hypoglycaemic episode. Given the extreme 
pressures on ward-based staff, particularly during busy 
periods, it can be difficult to adhere to a strict protocol that 
is utterly dependent upon close observation and impeccable 
timing. Finally, even if a hypoglycaemic episode is provoked 
and all samples timed correctly, the interpretation of 
biochemical and endocrine data can pose its own challenges. 
Ambiguity within the biochemical data often prompts a 
repeat prolonged fasting test. 
It is not easy to overcome the diagnostic challenges of 
TIH outlined here. Provocation of hypoglycaemia carries 
its own risks. This should only occur within a medical 
setting with appropriately trained staff, equipment and 
therapies. Accurate biomarkers of insulinoma and NICTs 
(through urinary metabolomics assessment for example) 
represents a possible future alternative diagnostic strategy 
to a prolonged fasting test. This could potentially avert 
the need to provoke hypoglycaemia. This should form a 
focus for future research: in theory, a reliable metabolomics 
signature of TIH sub-type should be possible, but will 
require much research in multiple cohorts and settings to 
show reliability, accuracy and clinical utility.
Management challenges
There are multiple challenges associated with the 
management of TIH. Underlying tumours (primarily 
insulinomas and occasionally NICTs) may be relatively 
small and therefore difficult to identify on imaging. In such 
cases, surgical resection may not be possible. Furthermore, 
in cases of loco-regional spread and/or metastases (rare with 
insulinoma, but commoner with NICTs), surgery may not 
be indicated or effective at removing the underlying cause 
of hypoglycaemia. Regarding medical therapies, sourcing 
relatively high doses of rhGH semi-urgently can pose its 
own challenges, especially if a specific funding request 
is required. Finally, patients and their relatives may find 
living with recurrent hypoglycaemia stressful. The need for 
lifestyle modification and regular glucose monitoring can 
be challenging, particularly in the context of underlying 
malignancy. For these reasons, patients with TIH may 
require additional psychological support.
Conclusions
To conclude, TIH is a rare form of recurrent hypoglycaemia 
stemming usually from underlying insulinoma or a NICT, 
that has important and potentially fatal implications for the 
patient. Although infrequently encountered outside of the 
Endocrine realm, in our view all healthcare professionals 
should be aware of TIH as a clinical entity. Such raised 
awareness amongst healthcare colleagues would help to 
avoid missed or delayed diagnoses, and facilitate prompt 
referral for focused Endocrine investigations. TIH demands 
accurate diagnosis given the diagnosis-dependent and 
individualised specific approaches to management. Where 
possible, we should usually strive for surgical resection 
of the underlying tumour in TIH, with such an approach 
offering the possibility of lifelong cure. Unfortunately, 
however, surgical resection is not always possible, and 
long-term medical therapies may be required. Although 
the diagnosis of TIH usually requires admission for a 
prolonged fasting test, future research should focus on 
alternate investigational routes to diagnosis, given the 
inherent challenges and potential safety concerns that an 
in-patient prolonged fasting test raises. Options include 
the possibility of recognition of specific metabolomics 
signatures of insulinoma and NICT, which if reliable 
and accurate enough, could even ultimately replace the 
prolonged fasting test for the future diagnosis of TIH 
and its subtypes. Future studies should also focus on the 
development of novel therapies for TIH, including proper 
assessment of the efficacy and safety of existing therapies 
(such as rhGH for NICT-induced TIH). Finally, we should 
always remember that behind every case of TIH there is 
a patient, with a family, loved ones and inner and outer 
social circles. Recurrent hypoglycaemia affects patients’ 
lives and potentially the lives of many others. Therefore, 
compassion and understanding of the human aspects of 
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